Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy for the Treatment of Metastatic Castration-Resistant Prostate Cancer

019.NMD.2022.D

This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy per the treating physician's discretion. Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physician's discretion.

2023-08-02

2024-08-02

2024-08-02

Recruiting

400

Inclusion Criteria: * 1. \>18 years of age * 2. Diagnosed with PSMA-positive metastatic castration-resistant prostate cancer and - has consented to undergo PSMA nuclear therapy per the treating physician. Specifically: * Metastatic or Locally Advanced AND Inoperable * Clear disease progression on PSMA-PET/CT * PSMA-PET/CT scan positive disease within 6 weeks * Labs: * Hemoglobin: \>8 g/dL * White blood cell count: \>2K cells/µL * Platelet (Thrombocyte) count: \>75 x 109/L * No prior therapy with Radium-223 Dichloride Exclusion Criteria: * Patients who do not meet the Inclusion Criteria laid out in section 4.2 will be excluded from the study.

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'OTHER', 'timePerspective': 'OTHER'}, 'enrollmentInfo': {'count': 400, 'type': 'ESTIMATED'}}

2023-10-23